Lead Product(s) : Bemcentinib
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Complete data analysis confirms that the primary endpoint of improved clinical response and key secondary endpoints were met in a subprotocol under the platform ACCORD2 study where bemcentinib was added to standard of care therapy.
Product Name : BGB324
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 26, 2022
Lead Product(s) : Bemcentinib
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Bemcentinib
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : University Hospital Southampton
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : In total, 179 eligible patients were enrolled across both studies between May 2020 and March 2021, randomly allocated on an open-label basis to treatment with bemcentinib in addition to standard of care (SoC) compared to SoC alone.
Product Name : BGB324
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 07, 2021
Lead Product(s) : Bemcentinib
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : University Hospital Southampton
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Bemcentinib
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Preclinical data suggest that bemcentinib is potentially useful for the treatment of early SARS-CoV-2 infection. There are currently no approved medical treatments for, or vaccines against, COVID-19.
Product Name : BGB324
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 28, 2020
Lead Product(s) : Bemcentinib
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Bemcentinib
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Bergenbio Confirms First Covid-19 Patient Dosed With Bemcentinib in Accord Trial
Details : Dosing has commenced in the UK Government-backed Phase II clinical trial assessing bemcentinib in hospitalised COVID-19 patients. Bemcentinib was selected as the first candidate to be tested as part of the ACcelerating COVID-19 Research & Development pla...
Product Name : BGB324
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 06, 2020
Lead Product(s) : Bemcentinib
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable